Literature DB >> 3626298

Acetate relaxation of isolated vascular smooth muscle.

J T Daugirdas, Z M Nawab.   

Abstract

The vasorelaxant effects of acetate in arginine vasopressin (AVP)-contracted rat tail artery strips were examined in order to study mechanism of action. Dose-dependent relaxation by acetate was found in the clinically important range of 4 to 16 mM. Relaxation was not due to complexing of ionized calcium, persisted after mechanical removal of the endothelium, and was not altered by pretreatment with indomethacin. Although acetate also inhibited contraction by alpha-1 and alpha-2 agonists, the relaxant effect was not altered by destruction of sympathetic nerve terminals using 6-hydroxydopamine. The degree of relaxation in this model by various anions correlated with their lyotropic properties; however, the vasorelaxant effect of acetate exceeded that which would be expected on the basis of its position in the lyotropic series. The vasorelaxant effect of acetate was shared by other short-chain fatty acids that can be conjugated with coenzyme A (CoA), such as propionate and malonate. In contrast, a much lesser or absent relaxant effect was found with nonfatty-acid precursors of acetyl CoA, such as pyruvate, lactate, and alanine. The vasorelaxant effect of acetate was abolished by pretreatment with DIDS, an inhibitor of organic anion uptake, suggesting that cellular uptake of acetate is essential to its vasorelaxant action. The results suggest that the relaxant effect of acetate in vascular smooth muscle is non-specific, is not mediated by prostaglandins, does not depend upon the presence of either endothelium or the sympathetic nervous system, and may be due to metabolism of acetate to acetyl CoA with attendant conversion of ATP to AMP.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3626298     DOI: 10.1038/ki.1987.169

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Short chained fatty acids and the colon: how do they cause vasodilatation?

Authors:  Christian Aalkjaer
Journal:  J Physiol       Date:  2002-02-01       Impact factor: 5.182

Review 2.  Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system.

Authors:  Maksymilian Onyszkiewicz; Kinga Jaworska; Marcin Ufnal
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-16

Review 3.  Beyond gut feelings: how the gut microbiota regulates blood pressure.

Authors:  Francine Z Marques; Charles R Mackay; David M Kaye
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 4.  The Gut Microbiota and Vascular Aging: A State-of-the-Art and Systematic Review of the Literature.

Authors:  Davide Agnoletti; Federica Piani; Arrigo F G Cicero; Claudio Borghi
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

5.  Acetate, a Short-Chain Fatty Acid, Acutely Lowers Heart Rate and Cardiac Contractility Along with Blood Pressure.

Authors:  Brian G Poll; Jiaojiao Xu; Seungho Jun; Jason Sanchez; Nathan A Zaidman; Xiaojun He; Laeben Lester; Dan E Berkowitz; Nazareno Paolocci; Wei Dong Gao; Jennifer L Pluznick
Journal:  J Pharmacol Exp Ther       Date:  2021-01-07       Impact factor: 4.030

Review 6.  From salt to hypertension, what is missed?

Authors:  Zhiyi Ma; Scott L Hummel; Ningling Sun; Yuanyuan Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-11-30       Impact factor: 3.738

7.  Reduced intestinal butyrate availability is associated with the vascular remodeling in resistance arteries of hypertensive rats.

Authors:  Patrizia Dardi; Rosangela Aparecida Dos Santos-Eichler; Sarah de Oliveira; Marco Aurélio Ramirez Vinolo; Niels Olsen Saraiva Câmara; Luciana Venturini Rossoni
Journal:  Front Physiol       Date:  2022-09-29       Impact factor: 4.755

8.  Microbial Interventions to Control and Reduce Blood Pressure in Australia (MICRoBIA): rationale and design of a double-blinded randomised cross-over placebo controlled trial.

Authors:  Dakota Rhys-Jones; Rachel E Climie; Paul A Gill; Hamdi A Jama; Geoffrey A Head; Peter R Gibson; David M Kaye; Jane G Muir; Francine Z Marques
Journal:  Trials       Date:  2021-07-27       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.